Zombie NIR™ Fixable Viability Kit

Pricing & Availability
Regulatory Status
RUO
Other Names
Fixable Dye, Fixable Viability Dye, Dead, Apoptosis
Ave. Rating
Submit a Review
Product Citations
publications
Zombie_NIR_Antibody_FC_062413
One day old C57BL/6 mouse splenocytes were stained with Zombie NIR™ and analyzed before fixation (purple) or after fixation and permeabilization (red). Cells alone, without Zombie NIR™ staining, are indicated in black.
  • Zombie_NIR_Antibody_FC_062413
    One day old C57BL/6 mouse splenocytes were stained with Zombie NIR™ and analyzed before fixation (purple) or after fixation and permeabilization (red). Cells alone, without Zombie NIR™ staining, are indicated in black.
See Zombie NIR™ spectral data
Cat # Size Price Quantity Check Availability Save
423105 100 tests 72€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
423106 500 tests 268€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Zombie NIR™ is an amine reactive fluorescent dye that is non-permeant to live cells, but permeant to the cells with compromised membranes. Thus, it can be used to assess live vs. dead status of mammalian cells. Zombie NIR™ is a polar water soluble dye, providing red fluorescence, making it suitable for multi-color detection.

Product Details
Technical Data Sheet (pdf)

Product Details

Preparation
Zombie NIR™ Fixable Viability kit is composed of lyophilized Zombie NIR™ dye and anhydrous DMSO. For reconstitution, bring the kit to room temperature; add 100 µl of DMSO to one vial of Zombie NIR™ dye until fully dissolved. 100 tests = 1 vial of Zombie NIR™ + DMSO, 500 tests = 5 vials of Zombie NIR™ + DMSO.
Storage & Handling
Store kit at -20°C upon receipt. Do not open vials until needed. Once the DMSO is added to the Zombie NIR™ dye, use immediately, or store at -20°C in a dry place and protected from light, preferably in a desiccator or in a container with desiccant for no more than one month.
Application

FC - Quality tested

Recommended Usage

Each lot of this product is quality control tested by immunofluorescent staining with flow cytometric analysis.

For flow cytometry, the suggested dilution is 1:100-1:1000 for 1-10 million cells. It is recommended that the reagent be titrated for optimal performance for each application, as optimal dosage varies with cell type.

Excitation Laser
Red Laser (633 nm)
Application Notes

Zombie NIR™ dye is excited by the red laser and has fluorescence emission maximum at 746 nm. If using in a multi-color panel design, filter optimization may be required depending on other fluorophores used. Zombie NIR™ dye has similar emission to APC/Cyanine7.

Standard Cell Staining Protocol:

  1. Prior to reconstitution, spin down the vial of lyophilized reagent in a microcentrofuge to ensure the reagent is at the bottom of the vial.
  2. For reconstitution, pre-warm the kit to room temperature; add 100 µL of DMSO to one vial of Zombie NIR™ dye and mix until fully dissolved
  3. Wash cells with PBS buffer (no Tris buffer and protein free).
  4. Dilute Zombie NIR™ dye at 1:100-1000 in PBS. Resuspend 1-10 x 106 cells in diluted 100 µL Zombie NIR™ solution. To minimize background staining of live cells, titrate the amount of dye and/or number of cells per 100 µL for optimal performance. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death.
    • Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS.
    • Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells.
  5. Incubate the cells at room temperature (or 4°C), in the dark, for 15-30 minutes.
  6. Wash one time with 2 mL BioLegend’s Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing serum or BSA.
  7. Continue performing antibody staining procedure as desired.
  8. Cells can be fixed with paraformaldehyde or methanol prior to permeabilization or can be analyzed without fixation.

No-wash Sequential Staining Protocol:

  1. Wash cells with PBS buffer (no Tris buffer and protein free).
  2. For reconstitution, pre-warm the kit to room temperature; add 100 µL of DMSO to one vial of Zombie NIR™ dye and mix until fully  dissolved
  3. Determine the total µL volume of antibody cocktail previously titrated and optimized for the assay that will be added to each vial/well of cells based on a final volume of 100 µL. Subtract that antibody volume from the 100 µL total staining volume intended for the assay. In the remaining volume, dilute Zombie NIR™ dye at 1:100-1000 in PBS as determined by prior optimization at that volume. For example, if you are adding 20 µL of antibody cocktail for a 100 µL total staining volume, use 80 µL of Zombie NIR™ solution. Resuspend 1-10 x 106 cells in the appropriate volume of Zombie NIR™ solution. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death.
    • Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS.
    • Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells.
  4. Incubate for 10-15 minutes at RT (or 4°C), protected from light. Without washing the cells, add the cell surface antibody cocktail and incubate for another 15-20 minutes.
  5. Add 1-2 mL Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing BSA or serum. Centrifuge to pellet.
  6. Continue with normal fixation and permeabilization procedure. If planning to skip fixation and analyze cells live, complete an additional wash step to minimize any unnecessary background of the live cells.
    • Notes: If the cell type in use cannot tolerate a protein-free environment, then titrate the Zombie NIR™ dye in the presence of the same amount of BSA/serum as will be present in the antibody staining procedure. A higher amount of Zombie NIR™ may be required since the BSA/serum will react with and bind up some proportion of the Zombie NIR™.
Additional Product Notes

View more applications data for this product in our Scientific Poster Library.

Application References
  1. McMaster SR, et al. 2015. PLoS One. 10:115725. PubMed
  2. Prado-Garcia H, et al. 2015. Anticancer Res.35:1529. PubMed
  3. Rodriguez-Rodriguez N, et al. 2015. J Immunol. 194:4207. PubMed
  4. Flies DB, et al. 2015. J Immunol. 194:5294. PubMed
Product Citations
  1. Rad S M AH, et al. 2020. PLoS One. 15:e0232915. PubMed
  2. Kim MY, et al. 2021. JCI Insight. 6:. PubMed
  3. Martínez-Vélez N, et al. 2022. Mol Cancer Ther. 21:471. PubMed
  4. Baratchart E, et al. 2022. PLoS Comput Biol. 18:e1009839. PubMed
  5. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  6. Rosina M, et al. 2022. Cell Metab. 34:533. PubMed
  7. Hsu MA, et al. 2022. Cancer Immunol Immunother. :. PubMed
  8. Zheng J, et al. 2022. Front Pharmacol. 13:866228. PubMed
  9. Komuczki J, et al. 2019. Immunity. 50:1289. PubMed
  10. Wang L, et al. 2020. Front Cell Dev Biol. 0.745138889. PubMed
  11. Iyer S, et al. 2021. Cancer Discov. 0.725. PubMed
  12. Headley M, et al. 2016. Nature. 531:513-517. PubMed
  13. Wu R, et al. 2022. J Dermatol. 49:432. PubMed
  14. Wang W, et al. 2022. Dev Cell. 57:228. PubMed
  15. Chaurio RA, et al. 2022. Immunity. 55:115. PubMed
  16. Cautivo KM, et al. 2022. Immunity. 55:254. PubMed
  17. Kuloglu ZE, et al. 2022. Allergy. 77:2459. PubMed
  18. Bayley R, et al. 2022. Mol Cell. 82:1924. PubMed
  19. Rodriguez-Tirado C, et al. 2022. Cancer Res. 82:2313. PubMed
  20. Tang Q, et al. 2022. Mol Ther. 30:2709. PubMed
  21. Gideon HP, et al. 2022. Immunity. 55:827. PubMed
  22. Zhang Y, et al. 2022. Nat Med. 28:1421. PubMed
  23. Sudmeier LJ, et al. 2022. Cell Rep Med. 3:100620. PubMed
  24. Naseem MU, et al. 2022. J Gen Physiol. 154: . PubMed
  25. Vukovic N, et al. 2022. J Biol Chem. 298:102153. PubMed
  26. Berger G, et al. 2022. Proc Natl Acad Sci U S A. 119:e2111003119. PubMed
  27. Hsieh T, et al. 2022. Front Immunol. 13:901030. PubMed
  28. Werder RB, et al. 2022. Sci Adv. 8:eabo6566. PubMed
  29. Zhu Y, et al. 2022. Immunology. 167:576. PubMed
  30. Ostendorf BN, et al. 2022. Nature. 611:346. PubMed
  31. Wang Z, et al. 2022. J Exp Med. 219: . PubMed
  32. Naranjo S, et al. 2022. Genes Dev. 36:936. PubMed
  33. Buckner CM, et al. 2022. Cell. 185:4333. PubMed
  34. VanDyke D, et al. 2022. Cell Rep. 41:111478. PubMed
  35. Wang W, et al. 2022. Cell Rep. 41:111582. PubMed
  36. Ogishi M, et al. 2023. J Exp Med. 220: . PubMed
  37. Zhu H, et al. 2023. Clin Transl Radiat Oncol. 38:138. PubMed
  38. Schaefer-Babajew D, et al. 2023. Nature. 613:735. PubMed
  39. Edwards SC, et al. 2023. J Exp Med. 220: . PubMed
  40. Naylor G, et al. 2022. Cancers (Basel). 14: . PubMed
  41. Ronning KE, et al. 2022. J Neuroinflammation. 19:299. PubMed
  42. Pleuger C, et al. 2022. Elife. 11: . PubMed
  43. Dutt TS, et al. 2022. Cell Rep. 41:111783. PubMed
  44. Xu Q, et al. 2023. Nat Immunol. 24:186. PubMed
  45. Hägglöf T, et al. 2023. Cell. 186:147. PubMed
  46. Schepers M, et al. 2023. Brain Behav Immun. 109:1. PubMed
  47. Gauthier L, et al. 2023. Nat Biotechnol. :. PubMed
  48. Ali LR, et al. 2023. J Exp Med. 220: . PubMed
  49. Zhou H, et al. 2023. Front Immunol. 13:1059687. PubMed
  50. Vyas M, et al. 2023. Front Immunol. 13:1098445. PubMed
  51. Rosain J, et al. 2023. Cell. 186:621. PubMed
  52. Ernst MPT, et al. 2023. Hemasphere. 7:e824. PubMed
  53. Babl N, et al. 2023. Front Oncol. 13:1107484. PubMed
  54. Dragan M, et al. 2022. J Invest Dermatol. 142:583. PubMed
  55. Parida PK, et al. 2022. Cell Metab. 34:90. PubMed
  56. Ma Y, et al. 2022. Am J Physiol Heart Circ Physiol. 322:H622. PubMed
  57. Salmon AJ, et al. 2022. Cancer Immunol Res. 10:597. PubMed
  58. Nelson LJ, et al. 2022. Cell Cycle. 21:1103. PubMed
  59. Kania AK, et al. 2022. J Immunol. 208:1873. PubMed
  60. Xu Y, et al. 2022. Bio Protoc. 12:e4354. PubMed
  61. McCafferty S, et al. 2022. Mol Ther. 30:2968. PubMed
  62. Pandey SP, et al. 2022. Cell Host Microbe. 30:1003. PubMed
  63. Knelson EH, et al. 2022. Cancer Immunol Res. 10:947. PubMed
  64. Sun Y, et al. 2022. STAR Protoc. 3:101479. PubMed
  65. Edwards KJ, et al. 2022. Cancer Immunol Res. 10:1084. PubMed
  66. Park G, et al. 2023. Photochem Photobiol. 99:850. PubMed
  67. Zhao Y, et al. 2022. J Neurosci. . PubMed
  68. Lutz EA, et al. 2022. Proc Natl Acad Sci U S A. 119:e2205983119. PubMed
  69. Sauter M, et al. 2022. STAR Protoc. 3:101664. PubMed
  70. Terminel MN, et al. 2022. BMC Neurosci. 23:58. PubMed
  71. Tan GMY, et al. 2022. Cancers (Basel). 14:. PubMed
  72. Prochazka L, et al. 2022. Mol Syst Biol. 18:e10886. PubMed
  73. Egli J, et al. 2022. MAbs. 14:2143009. PubMed
  74. Han X, et al. 2022. Nutrients. 14:. PubMed
  75. Li Y, et al. 2023. Adv Mater. 35:e2208923. PubMed
  76. Schönberger K, et al. 2023. Anal Chem. 95:4325. PubMed
  77. Tschanz F, et al. 2021. Cancer Res Commun. 1:164. PubMed
  78. Liu HJ, et al. 2023. Nat Commun. 14:1214. PubMed
  79. Tan J, et al. 2023. Acta Pharm Sin B. 13:632. PubMed
  80. Muri J, et al. 2023. Nat Immunol. 24:604. PubMed
  81. Zhou P, et al. 2023. Immunity. 56:669. PubMed
  82. Ananya A, et al. 2023. Immun Ageing. 20:10. PubMed
  83. Pasqual G, et al. 2023. Methods Mol Biol. 2618:71. PubMed
  84. Luo X, et al. 2023. Methods Mol Biol. 2618:133. PubMed
  85. Jiang X, et al. 2023. J Clin Invest. 133:. PubMed
  86. Pankhurst TE, et al. 2023. Cell Rep. 42:112310. PubMed
  87. Martins Nascentes Melo L, et al. 2023. J Immunother Cancer. 11:. PubMed
  88. Zhang YN, et al. 2023. Nat Commun. 14:1985. PubMed
  89. Onyshchenko K, et al. 2023. Nat Commun. 14:2087. PubMed
  90. Xu Z, et al. 2023. Cancers (Basel). 15:. PubMed
  91. Liu L, et al. 2023. J Exp Clin Cancer Res. 42:85. PubMed
  92. Glasner A, et al. 2023. Nat Immunol. 24:1020. PubMed
  93. Sugita M, et al. 2023. Cell Death Dis. 14:305. PubMed
  94. Lee K, et al. 2023. JCI Insight. 8:. PubMed
  95. Gao Y, et al. 2023. iScience. 26:106729. PubMed
  96. Changsheng H, et al. 2023. Sci Adv. 9:eade4186. PubMed
  97. Villalba N, et al. 2023. J Neuroinflammation. 20:127. PubMed
  98. Meckler JF, et al. 2023. Cancer Immunol Immunother. . PubMed
  99. Imai H, et al. 2023. iScience. 26:106822. PubMed
  100. Braun DJ, et al. 2023. PLoS One. 18:e0286495. PubMed
  101. Zhang TR, et al. 2023. Pharmaceuticals (Basel). 16:. PubMed
  102. Li JD, et al. 2023. Front Immunol. 14:1186393. PubMed
  103. Wu L, et al. 2023. Cell Res. . PubMed
  104. Cansever D, et al. 2023. Nat Immunol. . PubMed
  105. Liu X, et al. 2023. J Neuroinflammation. 20:144. PubMed
  106. Liu Y, et al. 2022. Signal Transduct Target Ther. 7:347. PubMed
  107. Li Q, et al. 2022. Cell Rep. 40:111308. PubMed
  108. He C, et al. 2022. Sci Adv. 8:eabm4552. PubMed
  109. Otano I, et al. 2021. Nat Commun. 12:7296. PubMed
  110. Zhou J, et al. 2021. Int J Med Sci. 18:3516. PubMed
  111. Landry LG, et al. 2021. Bio Protoc. 11:e3883. PubMed
  112. Kallemeijn WW, et al. 2019. Cell Chem Biol. 26:892. PubMed
  113. Kollareddy M, et al. 2017. Cancer Lett. 10.1016/j.canlet.2017.05.027. PubMed
  114. Barros-Martins J, et al. 2021. Nat Med. 27:1525. PubMed
  115. Nordengrün M, et al. 2021. Front Immunol. 12:651060. PubMed
  116. Roberts A, et al. 2021. Sci Rep. 11:4030. PubMed
  117. Ma Q, et al. 2021. Clin Transl Immunology. 10:e1300. PubMed
  118. Sheikh BN, et al. 2020. Nat Cell Biol. 22:828. PubMed
  119. Pathak JL, et al. 2021. Front Cell Dev Biol. 628139:9. PubMed
  120. Jiang C, et al. 2020. Int J Biol Sci. 2.802083333. PubMed
  121. Qiu J, et al. 2020. Cell Rep. 33:108465. PubMed
  122. Sagami S, et al. 2017. PLoS One. 10.1371/journal.pone.0169681. PubMed
  123. Lentucci C, et al. 2017. J Biol Chem. 292:2754-2772. PubMed
  124. Montes de Oca M, et al. 2016. Cell Rep. 17:399-412. PubMed
  125. Marco Barros R, et al. 2016. Cell. 167: 203-218. PubMed
  126. Gibb D, et al. 2016. EBioMedicine. 9: 77-86. PubMed
  127. Ajoge HO, et al. 2022. Viruses. 14:. PubMed
  128. Tan L, et al. 2022. Biochem Biophys Rep. 32:101351. PubMed
  129. Sauter M, et al. 2022. iScience. 25:103677. PubMed
  130. Stegelmeier AA, et al. 2022. Biomedicines. 10:. PubMed
  131. Chen L, et al. 2022. Mol Ther Oncolytics. 24:522. PubMed
  132. Sneller MC, et al. 2022. Nature. 606:375. PubMed
  133. Hamminger P, et al. 2021. J Autoimmun. 119:102610. PubMed
  134. Hu W, et al. 2021. Nat Immunol. 22:1163. PubMed
  135. Schalbetter SM, et al. 2022. Sci Adv. 8:eabi6672. PubMed
  136. Kilens S, et al. 2018. Nat Commun. 9:360. PubMed
  137. Merz SF, et al. 2019. Nat Commun. 10:2312. PubMed
  138. Barry KC, et al. 2018. Nat Med. 24:1178. PubMed
  139. Karlen SJ, et al. 2018. J Neuroinflammation. 15:344. PubMed
  140. Vishnoi M, et al. 2018. Cancer Res. 78:5349. PubMed
  141. Jimenez-Duran G, et al. 2020. EBioMedicine. 61:103039. PubMed
  142. Li JY, et al. 2020. J Clin Invest. 130:1767. PubMed
  143. Aguilera T, et al. 2016. Nat Commun. 7:13898. PubMed
  144. Abou-Hamad J, et al. 2022. iScience. 25:105524. PubMed
  145. Zou L, et al. 2022. Brain Behav Immun. 100:10. PubMed
  146. Son ET, et al. 2021. J Clin Invest. 131:. PubMed
  147. Majstrowicz K, et al. 2021. J Cell Sci. 134:. PubMed
  148. Daniel S, et al. 2021. Infect Immun. 89:e0016521. PubMed
  149. van der Heide V, et al. 2022. Cell Rep. :110508. PubMed
  150. Michaud D, et al. 2022. Front Immunol. 12:745873. PubMed
  151. Nagatake T, et al. 2022. Mucosal Immunol. 15:289. PubMed
  152. Watters JM, et al. 2021. Biochem Biophys Res Commun. 534:773. PubMed
  153. Fitzgerald AA, et al. 2021. J Immunother Cancer. 9:. PubMed
  154. Kodumudi KN, et al. 2019. Front Immunol. 10:1939. PubMed
  155. Liu HJ, et al. 2018. JCI Insight. 3. PubMed
  156. Agudelo M, et al. 2021. J Exp Med. :218. PubMed
  157. Gaebler C, et al. 2021. Nature. 639:591. PubMed
  158. Olingy C, et al. 2017. Sci Rep. 10.1038/s41598-017-00477-1. PubMed
  159. AC Belkina, JE Snyder-Cappione 2017. Cytometry A. 91:175-179. PubMed
  160. Weisberg SP, et al. 2020. Cell Reports. 29(12):3916-3932.e5.. PubMed
  161. Fukushima T, et al. 2019. Cell Rep. 29:4144. PubMed
  162. Halim L, et al. 2022. Front Immunol. 13:836549. PubMed
  163. Hemkemeyer SA, et al. 2020. J Biol Chem. 296:100136. PubMed
  164. Massafra V, et al. 2021. J Immunol. 207:493. PubMed
  165. Agudelo M, et al. 2022. J Exp Med. 219:. PubMed
  166. Glaubitz J, et al. 2022. Nat Commun. 13:4502. PubMed
  167. Woodruff MC, et al. 2022. Nature. :. PubMed
  168. García Nores GD, et al. 2018. Nat Commun. 9:1970. PubMed
  169. Verma M, et al. 2018. Cell Stem Cell. 23:530. PubMed
  170. Woodruff MC, et al. 2020. Nat Immunol. 1.920833333. PubMed
  171. Xu AQ, et al. 2020. Elife. 9:00. PubMed
  172. Si Y, et al. 2020. Sci Adv. 6:eaba0995. PubMed
  173. Pan H, et al. 2020. Mol Psychiatry. . PubMed
  174. Guarnaccia AD, et al. 2021. Cell Rep. 108636:34. PubMed
  175. Hering L, et al. 2021. Int J Mol Sci. 22:. PubMed
  176. Bouffi C, et al. 2015. J Immunol. 195: 2683-2695. PubMed
  177. Higuchi T, et al. 2015. Cancer Immunol Res. 3: 1257 - 1268. PubMed
  178. Patricio DO, et al. 2022. Front Immunol. 13:1042463. PubMed
  179. Kienzl M, et al. 2020. Oncoimmunology. 9:1776059. PubMed
  180. Beatson RE, et al. 2021. Cell Rep Med. 2:100473. PubMed
  181. Mahmoud W, et al. 2021. Cell Tissue Res. Online ahead of print. PubMed
  182. Jenkins RW, et al. 2018. Cancer Discov. 8:196. PubMed
  183. Retamal‐Díaz A, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01523. PubMed
  184. Wlodarska M et al. 2017. Cell host & microbe. 22(1):25-37 . PubMed
  185. Cousin N, et al. 2021. Cancer Res. 81:4133. PubMed
  186. Ostendorf BN, et al. 2020. Nat Med. 26:1048. PubMed
  187. Akiyama H, et al. 2020. J Virol. . PubMed
  188. Sperber HS, et al. 2020. FASEB J. 14615:34. PubMed
  189. Moreau GB, et al. 2020. Am J Trop Med Hyg. 103:1215. PubMed
  190. Miller EB, et al. 2021. J Neuroinflammation. 18:235. PubMed
  191. Mills C, et al. 2022. Cells. 11:. PubMed
  192. Pettinato G, et al. 2021. Sci Adv. 7:. PubMed
  193. Godoy-Pacheco A, et al. 2022. Oncol Lett. 24:288. PubMed
  194. Simonneau M, et al. 2018. Oncotarget. 9:36457. PubMed
  195. Koizumi SI, et al. 2018. Nat Commun. 9:5344. PubMed
  196. Chan JA, et al. 2020. Cell Rep Med. 1:100157. PubMed
  197. Michaud D, et al. 2020. Cytokine. 125:154817. PubMed
  198. Rao X, et al. 2022. Cell Death Dis. 13:891. PubMed
  199. Lisk C, et al. 2020. Front Immunol. 1.329166667. PubMed
  200. Adamik J, et al. 2022. Nat Commun. 13:5184. PubMed
  201. Sodji QH, et al. 2022. Cancer Res Commun. 2:725. PubMed
  202. Zhang Z, et al. 2021. Acta Pharm Sin B. 11:1965. PubMed
  203. Mahadevan NR, et al. 2021. Cancer Discov. 11:1952. PubMed
  204. Alansary M, et al. 2021. Dent Traumatol. 37:90. PubMed
  205. Le X, et al. 2021. J Thorac Oncol. 16:583. PubMed
  206. Song D, et al. 2021. Sci Rep. 11:22966. PubMed
  207. Yang S, et al. 2019. Nat Commun. 10:2782. PubMed
  208. Casella G, et al. 2017. Sci Rep. . 10.1038/s41598-017-16702-w. PubMed
  209. Aires V, et al. 2021. Front Immunol. 12:684430. PubMed
  210. Choi JE, et al. 2021. Nat Metab. 3:182. PubMed
  211. Ajina R, et al. 2021. Cancer Immunol Res. 9:386. PubMed
  212. Sato R, et al. 2020. Int Immunol. 499:32. PubMed
  213. Aregger M, et al. 2020. Nat Metab. 0.429861111. PubMed
  214. Alshetaiwi H, et al. 2020. Sci Immunol. 5:00. PubMed
  215. PRADO-GARCIA H, et al. 2015. Anticancer Res. 35:1529. PubMed
  216. Schadt L, et al. 2020. Cell Reports. 29(5):1236-1248.e7.. PubMed
  217. Grandclaudon M, et al. 2019. Cell. 179:432. PubMed
  218. Thyrsted J, et al. 2021. iScience. 24:103300. PubMed
  219. Basu A, et al. 2021. Cancer Immunol Res. Online ahead of print. PubMed
  220. Viant C, et al. 2021. J Exp Med. 218:. PubMed
  221. Nakajima T, et al. 2021. J Exp Med. 218:. PubMed
  222. Jie X, et al. 2022. J Immunother Cancer. 10:. PubMed
  223. Ferrer-Font L, et al. 2021. Curr Protoc. 1:e222. PubMed
  224. Wang K, et al. 2018. Medicine (Baltimore). 97:e0710. PubMed
  225. Bogie JF, et al. 2020. Ther Adv Chronic Dis. 11:2040622320947378. PubMed
  226. Xie Z, et al. 2020. Light Sci Appl. 0.486805556. PubMed
  227. Wang Z, et al. 2021. bioRxiv. . PubMed
  228. Littwitz-Salomon E, et al. 2021. Nat Commun. 12:5376. PubMed
  229. Steinbach K, et al. 2016. J Exp Med. 213: 1571 - 1587. PubMed
  230. Li Y, et al. 2022. J Neuroinflammation. 19:261. PubMed
  231. Yang J, et al. 2022. Microbiome. 10:149. PubMed
  232. Stinson WA, et al. 2022. JCI Insight. 7:. PubMed
  233. Kim S, et al. 2022. Redox Biol. 54:102347. PubMed
  234. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  235. Zeng Q, et al. 2022. Front Immunol. 13:740805. PubMed
  236. Christopher GA, et al. 2021. Biomolecules. 12:. PubMed
  237. Cho A, et al. 2021. Nature. Online ahead of print. PubMed
  238. Tavazoie MF, et al. 2018. Cell. 172:825. PubMed
  239. Clapes T, et al. 2021. Nat Cell Biol. 23:704. PubMed
  240. Woodruff M, et al. 2020. medRxiv. . PubMed
  241. McHugh D, et al. 2020. Life Sci Alliance. 3:00. PubMed
  242. English KG, et al. 2022. Biomedicines. 10:. PubMed
  243. Wan G, et al. 2021. Sci Rep. 11:22121. PubMed
  244. Hills LB, et al. 2021. J Immunol. 206:89. PubMed
  245. Kuhn JA, et al. 2021. Elife. 10:. PubMed
  246. Bosnjak B, et al. 2021. Front Immunol. 12:772240. PubMed
  247. Xu Y, et al. 2021. Front Immunol. 12:666991. PubMed
  248. Zhang H, et al. 2021. Cell Rep. 36:109708. PubMed
  249. Zhu S, et al. 2022. J Oncol. 2022:8724933. PubMed
  250. Espinoza J, et al. 2017. Oxidative Medicine and Cellular Longevity. 10.1155/2017/6781872. PubMed
  251. Pinder C, et al. 2017. J Immunol. 10.4049/jimmunol.1701253. PubMed
  252. Johnson AM, et al. 2020. J Immunol. 204:2295. PubMed
  253. Thompson EA, et al. 2021. Cell Rep. 108863:34. PubMed
  254. Popay TM, et al. 2021. Elife. 10: . PubMed
  255. Liu Y, et al. 2022. Front Oncol. 12:1037934. PubMed
  256. Elias G, et al. 2022. Elife. 11:. PubMed
  257. Nagatake T, et al. 2018. Int Immunol. 30:471. PubMed
  258. Ito Y, et al. 2018. Cell. 174:636. PubMed
  259. Cohen CA, et al. 2021. Nat Commun. 12:4678. PubMed
  260. Scharer CD, et al. 2020. Nat Commun. 3989:11. PubMed
  261. Rodríguez-Rodríguez N, et al. 2015. J Immunol. 194:4207. PubMed
  262. Lim JME, et al. 2022. Cell Rep Med. 3:100793. PubMed
  263. Vanekova L, et al. 2022. Methods Protoc. 5:. PubMed
  264. McGinnis CS, et al. 2019. Nat Methods. 1.096527778. PubMed
  265. Günther T, et al. 2019. PLoS Pathog. 15:e1007838. PubMed
  266. Fujimoto N, et al. 2020. PLoS Biol. 18:e3000704. PubMed
  267. Meyrath M, et al. 2020. Nat Commun. 2.564583333. PubMed
  268. Cui Z, et al. 2021. Cell Death Dis. 12:775. PubMed
  269. Mudd PA, et al. 2022. Cell. 185:603. PubMed
  270. Valestrand L, et al. 2022. Am J Pathol. . PubMed
  271. Espinal A, et al. 2022. Int J Mol Sci. 23:. PubMed
  272. Evgin L, et al. 2022. Sci Transl Med. 14:eabn2231. PubMed
  273. van Vloten JP, et al. 2019. Mol Ther Methods Clin Dev. 13:154. PubMed
  274. Akuffo AA, et al. 2018. J Biol Chem. 293:6187. PubMed
  275. Morganti JM, et al. 2019. J Neuroinflammation. 16:98. PubMed
  276. Muthalagu N, et al. 2020. Cancer Discov. 1.022222222. PubMed
  277. Evgin L, et al. 2020. Nat Commun. 2.671527778. PubMed
  278. Hemkemeyer SA, et al. 2020. J Biol Chem. . PubMed
  279. Luo G, et al. 2021. Sci Rep. 11:7841. PubMed
  280. Braun DA, et al. 2021. Cancer Cell. 39:632. PubMed
  281. Ruibal P, et al. 2016. Nature. 533: 100-104. PubMed
  282. Jalloh S, et al. 2022. PLoS Pathog. 18:e1010479. PubMed
  283. Ramachandran P, et al. 2019. Nature. 575:512. PubMed
  284. Qadir AS, et al. 2021. iScience. 24:103348. PubMed
  285. Lozano-Ojalvo D, et al. 2021. Cell Rep. 36:109570. PubMed
  286. Dieterle ME, et al. 2021. Elife. 10:. PubMed
  287. Sharma V, et al. 2021. ACR Open Rheumatol. 3:277. PubMed
  288. Clement CC, et al. 2021. Immunity. 54:721. PubMed
  289. Zhang YN, et al. 2021. Sci Adv. 7:eabj3107. PubMed
  290. Xueyang Yu et al. 2017. Immunity. 47(5):903-912 . PubMed
  291. Nagatake T, et al. 2018. J Allergy Clin Immunol. 142:470. PubMed
  292. Waight JD, et al. 2018. Cancer Cell. 33:1033. PubMed
  293. Manouchehri N, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  294. Mohammadi MR, et al. 2021. Commun Biol. 4:685. PubMed
  295. Noort RJ, et al. 2021. Front Cell Dev Biol. 9:659397. PubMed
  296. Soley BDS, et al. 2020. Br J Pharmacol. 177:3535. PubMed
  297. Lo CH, et al. 2021. Sci Rep. 6055:11. PubMed
  298. Salazar Y, et al. 2020. J Clin Invest. 130:3560. PubMed
  299. Bhattacharya P, et al. 2020. Elife. 9:00. PubMed
  300. Grubiši? V, et al. 2020. Cell Rep. 32:108100. PubMed
  301. Shim K, et al. 2017. Mol Ther. 10.1016/j.ymthe.2017.01.023. PubMed
  302. Tomić A, et al. 2016. PLoS Pathog. 12:e1006015. PubMed
  303. Filiano A, et al. 2016. Nature. 535:425-429. PubMed
  304. Armbruster N, et al. 2016. J Immunol. 196: 1284 - 1292. PubMed
  305. Tajima M, et al. 2022. Curr Protoc. 2:e540. PubMed
  306. Grajchen E, et al. 2020. J Neuroinflammation. 0.863888889. PubMed
  307. Su Y, et al. 2021. Clin Cancer Res. :clincanres.2241.2021. PubMed
  308. Dudek M, et al. 2021. Nature. 592:444. PubMed
  309. Jacobsen H, et al. 2021. Nat Commun. 12:4957. PubMed
  310. Cillo AR, et al. 2021. Cell Rep Med. 2:100476. PubMed
  311. Janssen JJE, et al. 2022. Am J Physiol Endocrinol Metab. 322:E141. PubMed
  312. Wang Z, et al. 2022. J Exp Med. 219:. PubMed
  313. He Y, et al. 2022. Cells. 11:. PubMed
  314. Zhang Y, et al. 2018. Front Microbiol. 9:2967. PubMed
  315. Rouleau N, et al. 2020. Immunohorizons. 0.695833333. PubMed
  316. Rizvi F, et al. 2021. Nat Commun. 0.925694444. PubMed
  317. Herland A, et al. 2020. Nat Biomed Eng. 421:4. PubMed
  318. Oherle K, et al. 2020. Immunity. 275:52. PubMed
  319. Wang Z, et al. 2021. Nature. 592:616. PubMed
  320. Ramos MIP, et al. 2021. Elife. 10:. PubMed
  321. Cloarec R, et al. 2016. PLoS One. 11: 0160176. PubMed
  322. Karanika S, et al. 2022. Front Immunol. 13:972266. PubMed
  323. Ghezraoui H, et al. 2018. Nature. 560:122. PubMed
  324. Manuszak C, et al. 2020. J Biol Methods. 7:e131. PubMed
  325. Reuschl AK, et al. 2022. Cell Rep. 39:110650. PubMed
  326. Tang JS, et al. 2022. Front Immunol. 13:946713. PubMed
  327. Wang Z, et al. 2021. Nature. 595:426. PubMed
  328. Mumby MJ, et al. 2021. J Virol. 95:e0058821. PubMed
  329. Chou TW, et al. 2021. Cell Death Dis. 12:756. PubMed
  330. Leary N, et al. 2022. J Extracell Vesicles. 11:e12197. PubMed
  331. Hobbs BE, et al. 2021. Pathogens. 10:. PubMed
  332. Fan ZP, et al. 2021. Front Immunol. 12:743354. PubMed
  333. McKenzie MD, et al. 2019. Cell Stem Cell. 25:258. PubMed
  334. Zischke J, et al. 2017. PLoS Pathogens. 13(6):e1006454. PubMed
  335. Lien TS, et al. 2021. Front Immunol. 12:618577. PubMed
  336. Phan TS, et al. 2021. Sci Adv. 7:. PubMed
  337. Luo L, et al. 2021. J Neuroinflammation. 18:27. PubMed
  338. Suzuki T, et al. 2017. Cell Rep. 18(8):2045-2057. PubMed
  339. McMaster S, et al. 2015. PLoS One. 10:115725. PubMed
  340. Renner K, et al. 2020. Cell Reports. 29(1):135-150.e9.. PubMed
  341. Wang R, et al. 2022. J Immunother Cancer. 10:. PubMed
  342. Denoth-Lippuner A, et al. 2021. Cell Stem Cell. 28:2020. PubMed
  343. Zhang Y, et al. 2022. Mater Today Bio. 15:100317. PubMed
  344. Smith KJ, et al. 2022. PLoS Biol. 20:e3001554. PubMed
  345. Madsen CS, et al. 2022. Commun Biol. 5:888. PubMed
  346. Maas RR, et al. 2021. Nat Protoc. 16:4692. PubMed
  347. Lee HY, et al. 2021. Curr Protoc. 1:e272. PubMed
  348. Mujal AM, et al. 2022. Cancer Immunol Res. 10:403. PubMed
  349. Daniels M, et al. 2017. Sci Rep.. 10.1038/s41598-017-17387-x. PubMed
  350. Hering L, et al. 2020. Front Immunol. 1.747222222. PubMed
  351. Korin B, et al. 2020. Sleep. :43. PubMed
  352. Santopaolo M, et al. 2021. Front Immunol. 609406:12. PubMed
  353. Donlan AN, et al. 2021. JCI Insight. 6: . PubMed
  354. Lisk C, et al. 2021. Front Immunol. 12:624197. PubMed
  355. Flies D, et al. 2015. J Immunol. 194:5294. PubMed
  356. Chou DB, et al. 2022. Nat Commun. 13:6021. PubMed
  357. Bryan AF, et al. 2020. Nucleic Acids Res. 48:2924. PubMed
  358. Sontheimer-Phelps A, et al. 2019. Cell Mol Gastroenterol Hepatol. 9:507. PubMed
  359. Han P, et al. 2020. Sci Adv. 6:eaaz1580. PubMed
  360. Eckert EC, et al. 2020. Mol Ther Oncolytics. 0.710416667. PubMed
  361. Chakraborty A, et al. 2022. Methods Mol Biol. 2442:565. PubMed
  362. Li X, et al. 2022. Oncoimmunology. 11:2118210. PubMed
  363. Kiesel VA, et al. 2022. Front Oncol. 12:767479. PubMed
  364. Gutierrez-Prat N, et al. 2022. Life Sci Alliance. 5:. PubMed
  365. Viant C, et al. 2020. Cell. 183:1298. PubMed
  366. Heckler M, et al. 2021. Cancer Discov. Online ahead of prin. PubMed
  367. Maller O, et al. 2020. Nat Mater. 20:548. PubMed
  368. Gaebler C, et al. 2020. bioRxiv. . PubMed
  369. Shimada BK, et al. 2020. Immunohorizons. 0.55625. PubMed
  370. Jeffery H, et al. 2017. Clin Exp Immunol. 10.1111/cei.12940. PubMed
  371. Hosking M, Flynn C, Whitton J 2016. PLoS Pathog. 12: 1005861. PubMed
  372. Wachowska M, et al. 2020. Cancer Immunol Immunother. 69:1101. PubMed
  373. Qin J, et al. 2020. Cancer Immunol Res. 8:1426. PubMed
  374. Spiljar M, et al. 2021. Cell Metab. 33:2231. PubMed
  375. Kastenschmidt JM, et al. 2021. Cell Rep. 35:108997. PubMed
  376. Kerdidani D, et al. 2022. J Exp Med. 219:. PubMed
  377. Sibler E, et al. 2022. Cancers (Basel). 14:. PubMed
  378. Spath S, et al. 2022. iScience. 25:104998. PubMed
  379. Chou DB, et al. 2020. Nat Biomed Eng. 0.440277778. PubMed
  380. Gangoso E, et al. 2021. Cell. 184:2454. PubMed
  381. Sibler E, et al. 2021. Cells. 10:. PubMed
  382. Farrand K, et al. 2022. Curr Protoc. 2:e482. PubMed
  383. Binnewies M, et al. 2019. Cell. 177:556. PubMed
  384. Patterson DG, et al. 2021. J Immunol. 207:1798. PubMed
  385. Zhang N, et al. 2022. Front Immunol. 13:926368. PubMed
  386. Cho A, et al. 2022. J Exp Med. 219:. PubMed
  387. Celias DP, et al. 2022. STAR Protoc. 3:101464. PubMed
  388. Erens C, et al. 2022. Biomedicines. 10:. PubMed
  389. Zhou P, et al. 2022. Sci Transl Med. :eabi9215. PubMed
  390. Sauler M, et al. 2022. Nat Commun. 13:494. PubMed
  391. Guarnaccia AD, et al. 2021. STAR Protoc. 2:101000. PubMed
  392. Zhang L, et al. 2021. Mol Ther. 29:744. PubMed
  393. Gamradt S, et al. 2021. iScience. 24:103312. PubMed
  394. Li H, et al. 2021. Signal Transduct Target Ther. 6:389. PubMed
  395. Muchowicz A, et al. 2017. Eur J Cancer. 10.1016/j.ejca.2017.06.004. PubMed
  396. Goddery EN, et al. 2021. Front Immunol. 12:726421. PubMed
  397. Xie Z, et al. 2020. Light Sci Appl. 9:161. PubMed
  398. Dar HH, et al. 2021. Redox Biol. 45:102045. PubMed
  399. Clutton G, et al. 2016. Sci Rep. 6:30749. PubMed
  400. Quijano-Rubio A, et al. 2022. Nat Biotechnol. Online ahead of print. PubMed

Antigen Details

Biology Area
Apoptosis/Tumor Suppressors/Cell Death, Cell Biology, Neuroscience
Gene ID
NA

Related FAQs

I am concerned about the spillover I am observing from the Zombie dye into its neighboring channels.
Rule of thumb with Zombie dyes is to titrate them down as much as possible to fit your application. This should potentially help with spillover. Secondly, Zombie positive events represent dead cells and are typically gated out from analysis.
How does the performance of your Zombie dye compare with competitors?

Zombie dyes have been tested against other leading competitors' fixable viability kits and given comparable results. We also highly recommend that you titrate down the amount of each dye used in order to best match the negative signals of your unstained sample and MFI- (mean fluorescence intensity) stained samples.

Can I use methanol/ethanol for fixation after using a Zombie dye?

Yes, most fixation reagents are fine to be used with Zombie dyes. However, it should be noted that Zombie dyes can still be sensitive to reactive oxygen species. Light exposure or reagents with hydrogen peroxide can lead to free radical formation, affecting fluorescence.

Can Zombie be used to determine bacteria, yeast viability?
We have not tested in house bacterial or yeast viability using Zombie dyes. It is not clear whether the difference between surface and intracellular signals will be significantly different in case of non mammalian cells.
Can I use Zombie with cells suspension containing serum?
Serum is full of proteins which will sequester the dye and thereby reducing its effective concentration. The basic rule of thumb with zombie is to titrate it based on your specific condition. Titration also helps reduce the background and spillover into other channels.
Can I use Zombie dyes for microscopy?

Zombie dyes tested in-house for microscopy applications will display data on the product technical datasheet. It should be noted that Zombie dyes may not work for dead cell discrimination in every microscopy application. Important considerations that may impact analysis are determining the signal level that constitutes a dead cell and identifying the proper plane to observe the dead cells.

Why can't I fix my cells prior to using Zombie dyes?

The fixation process can contort and alter the membrane of cells, effectively rendering them dead. Since the ability of the Zombie dyes to stain dead cells is correlated with cell permeability, your results may no longer be a valid representation of dead versus live cells.

Can I use Zombie dyes to detect apoptotic cells?

Yes, Zombie dyes can be used with apoptosis markers, such as Annexin V or Apotracker™ (shown below), to discriminate live, apoptotic, and dead cells.

One day-old C57BL/6 mouse thymocytes were stained with Apotracker™ Tetra Alexa Fluor® 647 and Zombie™ YG581. Zombie-dim/Apotracker™-positive cells are apoptotic, while double-positive cells are dead. Live cells are negative for both markers.

How should I store Zombie dyes?

Store the Zombie dye kit at -20°C upon receipt. Do not open vials until needed. Once DMSO is added, use immediately or store at -20°C in a dry place and protected from light, preferably in a desiccator or in a container with desiccant for no more than one month.

Go To Top Version: 7    Revision Date: 12.18.2024

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account